Diligence memo · auto-generated · as of July 2, 2026
MAPS Public Benefit Corp
MAPS Public Benefit Corp looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
MAPS Public Benefit Corp operates in Pharmaceuticals, based in SAN JOSE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
MAPS Public Benefit Corp has raised $215M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $215M on 2023-09-15.
Most recent recorded round closed around 2023-09-15.
Valuation (modeled)modeled
Provath models MAPS Public Benefit Corp at approximately $2.9B (range $1.0B–$4.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.53× the median modeled value of Series D+ Pharmaceuticals companies in 2022–2024 (18 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.8 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 97% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Paragon Biosciences Emalex Capital, Inc., TrialSpark, Inc., Fog Pharmaceuticals, Inc., Karyopharm Therapeutics Inc., ADARx Pharmaceuticals, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.